Study of the Presence and Extent of Corneal Disturbance Associated With B+L Biotrue MPS Used With B+L PureVision Lenses
NCT ID: NCT01268306
Last Updated: 2016-08-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
8 participants
INTERVENTIONAL
2010-10-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Although the clinical significance of staining is debated, most clinicians agree that less staining is preferable to greater amounts of staining. Advances in understanding as well as the specifics of lens care product formulation ideally will have resulted in design of newer products that minimize corneal staining and maximize product performance. This study will examine rates of corneal staining using B+L's recently introduced lens care product: BioTrue with the B+L PureVision lens which has previously been associated with the highest levels of staining.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Short-Term Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions
NCT01240122
Clinical Biocompatibility Evaluation of Contact Lens Coatings
NCT03034928
7-Day, Multi-Site Study of an Investigational Multi-Purpose Disinfecting Solution for Contact Lens Wearers
NCT00884806
Three Daily Wear Monthly Replacement Silicone Hydrogel Contact Lenses With Two Multi-purpose Disinfecting Solution Combinations
NCT04789382
Comparative Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions
NCT01024855
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Although the clinical significance of staining is debated, most clinicians agree that less staining is preferable to greater amounts of staining. Advances in understanding as well as the specifics of lens care product formulation ideally will have resulted in design of newer products that minimize corneal staining and maximize product performance. This study will examine rates of corneal staining using B+L's recently introduced lens care product: BioTrue with the B+L PureVision lens which has previously been associated with the highest levels of staining.
This pilot study is intended to assess the presence of corneal staining among patients who are using BioTrue solution
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
B+L Biotrue MPS and B+L PureVision
Successful contact lens wearers switched to B\&L BioTrue MPS while wearing B+L PureVision lenses
B+L Biotrue MPS and B+L PureVision
Subjects use Bausch \& Lomb (B+L) Biotrue MPS with B+L PureVision contact lenses
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
B+L Biotrue MPS and B+L PureVision
Subjects use Bausch \& Lomb (B+L) Biotrue MPS with B+L PureVision contact lenses
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects 18 years of age or older.
3. Subjects may be of either sex and of any race.
4. History (within the past 6 months) of successful soft contact lens wear.
5. Subjects must be free of any ocular disorder that would contraindicate contact lens wear
6. Subjects must have grade 1 (trace) or less corneal staining at baseline measurement as determined by the investigator or subinvestigator
7. Ocular health within normal limits as determined by the investigator or subinvestigator.
8. Willing to wear test contact lenses and use test lens care product throughout the length of the study period.
Exclusion Criteria
2. Inability to comfortably tolerate test lenses or lens care product.
3. Inability or unwillingness to follow all study instructions and complete study visits as required.
4. Greater than grade 1 (trace) staining in any quadrant at baseline examination.
5. Presumed or actual ocular infection (bacterial, viral, or fungal) or history of ocular herpes in either eye as determined by subject history and/or examination.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
Epstein, Arthur B., OD, FAAO
INDIV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arthur B. Epstein, OD
Role: PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Joel J. Ackerman, OD, PC
Phoenix, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLC-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.